RalB GTPase-Mediated Activation of the IκB Family Kinase TBK1 Couples Innate Immune Signaling to Tumor Cell Survival

Department of Cell Biology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390, USA.
Cell (Impact Factor: 33.12). 11/2006; 127(1):157-70. DOI: 10.1016/j.cell.2006.08.034
Source: PubMed

ABSTRACT The monomeric RalGTPases, RalA and RalB are recognized as components of a regulatory framework supporting tumorigenic transformation. Specifically, RalB is required to suppress apoptotic checkpoint activation, the mechanistic basis of which is unknown. Reported effector proteins of RalB include the Sec5 component of the exocyst, an octameric protein complex implicated in tethering of vesicles to membranes. Surprisingly, we find that the RalB/Sec5 effector complex directly recruits and activates the atypical IkappaB kinase family member TBK1. In cancer cells, constitutive engagement of this pathway, via chronic RalB activation, restricts initiation of apoptotic programs typically engaged in the context of oncogenic stress. Although dispensable for survival in a nontumorigenic context, this pathway helps mount an innate immune response to virus exposure. These observations define the mechanistic contribution of RalGTPases to cancer cell survival and reveal the RalB/Sec5 effector complex as a component of TBK1-dependent innate immune signaling.

Download full-text


Available from: Gladys Mirey, Aug 23, 2015
  • Source
    • "RalB has been shown to be involved in many important biological processes such as the host immune response (Chien et al., 2006), tumorigenesis (Peschard et al., 2012), tumor cell invasion and metastasis (Bodemann and White, 2008; Neel et al., 2012), control of autophagy (Bodemann et al., 2011), and exocytosis (Martin et al., 2012). Despite controlling diverse biological functions , RalB is only known to interact with a limited number of effector proteins (Martin and Der, 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Diverse environmental cues converge on and are integrated by the mTOR signaling network to control cellular growth and homeostasis. The mammalian Tsc1-Tsc2 GTPase activating protein (GAP) heterodimer is a critical negative regulator of Rheb and mTOR activation. The RalGAPα-RalGAPβ heterodimer shares sequence and structural similarity with Tsc1-Tsc2. Unexpectedly, we observed that C. elegans expresses orthologs for the Rheb and RalA/B GTPases and for RalGAPα/β, but not Tsc1/2. This prompted our investigation to determine whether RalGAPs additionally modulate mTOR signaling. We determined that C. elegans RalGAP loss decreased lifespan, consistent with a Tsc-like function. Additionally, RalGAP suppression in mammalian cells caused RalB-selective activation and Sec5- and exocyst-dependent engagement of mTORC1 and suppression of autophagy. Unexpectedly, we also found that Tsc1-Tsc2 loss activated RalA/B independently of Rheb-mTOR signaling. Finally, RalGAP suppression caused mTORC1-dependent pancreatic tumor cell invasion. Our findings identify an unexpected crosstalk and integration of the Ral and mTOR signaling networks.
    Molecular cell 12/2013; 53(2). DOI:10.1016/j.molcel.2013.12.004 · 14.46 Impact Factor
  • Source
    • "Accumulating evidence demonstrates that TBK1 and IKKE play important roles in tumorigenesis and survival [6] [9] [10] [24] [25] and are expressed by tumor cells under stressful growth conditions [8] including those that predominate in the HSC niche [26] [27] [28]. To evaluate whether the binding of PCa cells to niche osteoblasts induces the expression of TBK1 and IKKE in PCa cells, PCa cells were co-cultured with ST2 cells and then analyzed by qPCR. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The mechanisms that regulate hematopoietic stem cell (HSC) dormancy and self-renewal are well established and are largely dependent on signals emanating from the HSC niche. Recently, we found that prostate cancer (PCa) cells target the HSC niche in mouse bone marrow (BM) during metastasis. Little is known, however, as to how the HSC niche may regulate dormancy in cancer cells. In this study, we investigated the effects of TANK binding kinase 1 (TBK1) on PCa dormancy in the BM niche. We found that binding with niche osteoblasts induces the expression of TBK1 in PCa cells PC3 and C4-2B. Interestingly, TBK1 interacts with mammalian target of rapamycin (mTOR) and inhibits its function. Rapamycin, an mTOR inhibitor, induces cell cycle arrest of PCa cells and enhances chemotherapeutic resistance of PCa cells. As a result, the knockdown of TBK1 decreases PCa stem-like cells and drug resistance in vitro and in vivo. Taken together, these results strongly indicate that TBK1 plays an important role in the dormancy and drug resistance of PCa.
    Neoplasia (New York, N.Y.) 09/2013; 15(9):1064-74. DOI:10.1593/neo.13402 · 5.40 Impact Factor
  • Source
    • "In addition to its well-known role in inflammation, NF-κB activation also influences cell survival, cell cycle progression, and proliferation. Indeed, there is an extensive cross talk between NF-κB components and growth factor signaling and cell cycle pathways [38] [39] [40] [41] [42] [43]. Activation of NF-κB also regulates cell cycle progression and cell proliferation by mechanisms that include the expression of cytokines that promote proliferation of tumor cells [44– 46] and by inducing expression of cyclin D1 and c-Myc [47] [48]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Tumor necrosis factor receptor 1 (TNFR1)-associated death domain protein (TRADD) is an important adaptor in TNFR1 signaling and has an essential role in nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation and survival signaling. Increased expression of TRADD is sufficient to activate NF-κB. Recent studies have highlighted the importance of NF-κB activation as a key pathogenic mechanism in glioblastoma multiforme (GBM), the most common primary malignant brain tumor in adults.We examined the expression of TRADD by immunohistochemistry (IHC) and find that TRADD is commonly expressed at high levels in GBM and is detected in both cytoplasmic and nuclear distribution. Cytoplasmic IHC TRADD scoring is significantly associated with worse progression-free survival (PFS) both in univariate and multivariate analysis but is not associated with overall survival (n = 43 GBMs). PFS is a marker for responsiveness to treatment. We propose that TRADD-mediated NF-κB activation confers chemoresistance and thus a worse PFS in GBM. Consistent with the effect on PFS, silencing TRADD in glioma cells results in decreased NF-κB activity, decreased proliferation of cells, and increased sensitivity to temozolomide. TRADD expression is common in glioma-initiating cells. Importantly, silencing TRADD in GBM-initiating stem cell cultures results in decreased viability of stem cells, suggesting that TRADD may be required for maintenance of GBM stem cell populations. Thus, our study suggests that increased expression of cytoplasmic TRADD is both an important biomarker and a key driver of NF-κB activation in GBM and supports an oncogenic role for TRADD in GBM.
    Neoplasia (New York, N.Y.) 08/2013; 15(8):888-97. DOI:10.1593/neo.13608 · 5.40 Impact Factor
Show more